1. Scrip
  2. >>Business
  3. >>Financing

Interview: iTeos Attracts Investors By Targeting TIGIT

Series B2 Financing Raises $125m

 
• By Kevin Grogan

The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.

Shovel_Money
Belgium's iTeos In The Money • Source: Shutterstock

The excitement surrounding the potential of TIGIT in the new wave of immuno-oncology therapies has helped iTeos Therapeutics SA raise another $125m to advance its pipeline.

The Belgian biotech has closed a series B2 financing that was co-led by new investors RA Capital Management and Boxer Capital

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.